FierceBiotech 8. Apr. 2026 With $2B Novo deal in the books, Vivtex isn't 'limited to being just a drug delivery company': CEO
FierceBiotech 8. Apr. 2026 Astellas unearths Dyno muscle disorder AAV capsid with $15M option agreement
FierceBiotech 8. Apr. 2026 Akari locks arms with WuXi XDC to develop and manufacture novel ADC treatment
FierceBiotech 8. Apr. 2026 Jeito hails $1.2B as 'largest raise ever' for independent biopharma-focused European fund
FierceBiotech 8. Apr. 2026 OrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugates
FierceBiotech 8. Apr. 2026 With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'
FierceBiotech 7. Apr. 2026 Lilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinic
FierceBiotech 7. Apr. 2026 Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study
FierceBiotech 6. Apr. 2026 Takeda tears up Denali partnership, returning dementia asset amid restructuring
FierceBiotech 6. Apr. 2026 AI model designs new treatment candidate for opioid addiction that cuts cravings in rats
FierceBiotech 6. Apr. 2026 With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine
FierceBiotech 6. Apr. 2026 US, UK regulators bolster medical device collaboration while lifting tariffs